METHODS: A single-center, pre- vs. post-period pragmatic trial at Weill-Cornell Medical Center assessed usual care for consecutively enrolled admitted ABSSSI patients during an observational period (pre-period). Identification and treatment of eligible admitted ABSSSI patients with dalbavancin were implemented in the post-period. Those with life-threatening infections, requiring multiple antibiotics/intensive care, or with unstable comorbidities were excluded. Outcomes were assessed over a 44-day follow-up period.
RESULTS: Of 48 and 43 patients enrolled, respectively, in the pre- and post-periods, mean infection-related LOS was reduced in the post-period (3.2 days vs. 4.8 days; P = 0.003). Similar results were found in an adjusted LOS analysis. Work productivity and activity impairment outcomes significantly improved in the post-period (P ≤ 0.01). Complete response rates were similar: 50% (pre-period) and 57% (post-period). Among AEs identified, 17% (n = 7) were found to have possible causal relation to dalbavancin in the post-period. Few AEs were serious (n = 3; 7% post-period versus n = 1; 2% pre-period).
CONCLUSIONS: After implementing the ENHANCE ABSSSI pathway, LOS was significantly reduced by almost 2 days, with potential improvements in work productivity and ability to complete daily activities.
BACKGROUND: ClinicalTrials.gov identifier, NCT03233438.
BACKGROUND: Allergan plc.
方法:单中心,前vs.Weill-Cornell医学中心的期后务实试验评估了观察期间(期前)连续纳入的ABSSSI入院患者的常规治疗.在术后阶段,对符合条件的入院ABSSSI患者进行了达巴万星的鉴定和治疗。那些感染危及生命的人,需要多种抗生素/重症监护,或不稳定的合并症被排除。在44天的随访期内评估结果。
结果:在48和43名患者中,分别,在前期和后期,术后平均感染相关LOS降低(3.2天vs.4.8天;P=0.003)。在调整后的LOS分析中发现了类似的结果。工作生产率和活动障碍结果在后期显着改善(P≤0.01)。完全缓解率相似:50%(期前)和57%(期后)。在确定的AE中,在后期发现17%(n=7)与达巴万宁可能有因果关系。很少有严重的AE(n=3;7%的期后对n=1;2%的期前)。
结论:实施ENHANCEABSSSI途径后,LOS显著减少了近2天,提高工作效率和完成日常活动的能力。
背景:ClinicalTrials.gov标识符,NCT03233438。
背景:Allerganplc.